Circio Holding ASA
↗Lysaker, Norway
Circio (formerly Targovax ASA) is a Norwegian clinical-stage biotechnology company pioneering the development of circular RNA (circRNA) therapeutics and oncolytic virus-based immunotherapies for oncology and other difficult-to-treat diseases. The company rebranded in May 2023 to reflect its strategic focus on accelerating development of its proprietary circular RNA platform. Circio's core technology platforms include circVec (a modular genetic cassette for circRNA generation) and circAde (engineered adenovirus delivery system for circRNA to cancer cells), which enable the development of next-generation nucleic acid medicines. The company operates with approximately 9 employees and is focused on clinical development of its pan-RAS cancer vaccine (TG01) and oncolytic virus immunotherapy (ONCOS-102) for multiple cancer indications including pancreatic cancer, multiple myeloma, melanoma, and mesothelioma.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology, RNA Therapeutics, Immuno-oncology
SIZE & FINANCIALS
Employees:1-50
Founded:2010
Ownership:public
Status:operating
FUNDING
Stage:Public Company
Investors:HealthCap, Lifeline Ventures, Atlas Special Opportunities LLC
STOCK
Exchange:Oslo Stock Exchange (Euronext)
Ticker:CRNA (formerly TRVX)
Market Cap:$15.6M
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1/2
Modalities:circRNA, Oncolytic Virus, Cancer Vaccine, ADV-based delivery
Active Trials:4
Trial Phases:Phase 1: 2 | Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Agenus (QS-21 STIMULON adjuvant collaboration for TG01), Oslo University Hospital (TG01 Phase 1/2 in multiple myeloma), University of Kansas Cancer Center / Georgetown University (TG01 pancreatic/lung cancer trials), Karolinska Institutet (circRNA research collaboration with Prof Michael Uhlin)
COMPETITION
Position:Niche Player
Competitors:Moderna, BioNTech, Orna Therapeutics, Translate Bio (Sanofi subsidiary), Other circRNA and mRNA therapeutic companies
LEADERSHIP
Key Executives:
Dr. Erik Digman Wiklund - Chief Executive Officer
Dr. Thomas B Hansen - VP & Head of Research
Lubor Gaal - Chief Financial Officer
Scientific Founders:Dr. Erik Digman Wiklund (CEO, circRNA co-discoverer), Dr. Thomas B Hansen (VP Research, circRNA co-discoverer)
Board Members:Erik Wiklund (Board Member), Damian John Marron (Chairman), Robert Forbes Burns (Board Member), Diane Mary Mellett (Board Member), Thomas Falck (Board Member)
LINKS
Website:targovax.com
Crunchbase:Crunchbase Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Circio Holding ASA. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.